WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Iowa law allows police to arrest and deport migrants. Civil rights groups are suingI'm a vet and here's how to keep your dog safe in warmer weatherCanucks overcome 3Royal Navy nuclear submarine officer who killed two young women with car is jailed for 10 yearsBride calls out wedding guest's 'disrespectful' RSVP: 'This is not how invitations work'Labour MP Jess Phillips admits she could LOSE her Birmingham seat if a proCan renting your entire wardrobe make you more stylish... and save you money?Moaners rejoice! Ranting with your friends can actually make you happier, study findsActivist investor wins 3 Norfolk Southern board seats but won’t have control to fire CEOThe Taliban warn journalists, experts against cooperating with Afghanistan International TV